Literature DB >> 1708483

A monoclonal antibody to common acute lymphoblastic leukemia antigen (neutral endopeptidase) immunostains senile plaques in the brains of patients with Alzheimer's disease.

M Sato1, K Ikeda, S Haga, D Allsop, T Ishii.   

Abstract

We immunostained brain tissues of patients with Alzheimer's disease (AD) together with non-demented aged and younger controls with a battery of anti-human hemopoietic cell monoclonal antibodies (OK series, Ortho Diagnostics Co., Ltd. and some others) by the avidin-biotin-peroxidase complex (ABC) method to see if any epitopes are shared with the nervous system or might contribute to the neurodegenerative changes in this disease. One out of 29 monoclonal antibodies, OKBcALLa, which recognizes common acute lymphocytic leukemia antigen (CALLA, CD10), immunostained senile plaques in the brains of patients with AD. The pattern and intensity of this staining, using cryopreserved samples, was almost identical to that obtained with anti beta-protein. Thus, senile plaques in the Alzheimer's brain share an epitope with CALLA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1708483     DOI: 10.1016/0304-3940(91)90702-u

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain.

Authors:  Suqing Wang; Rui Wang; Lang Chen; David A Bennett; Dennis W Dickson; Deng-Shun Wang
Journal:  J Neurochem       Date:  2010-07-30       Impact factor: 5.372

Review 2.  Distribution of beta/A4 protein and amyloid precursor protein in hereditary cerebral hemorrhage with amyloidosis-Dutch type and Alzheimer's disease.

Authors:  A J Rozemuller; R A Roos; G T Bots; W Kamphorst; P Eikelenboom; W E Van Nostrand
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

3.  Development of [125I]RB104, a potent inhibitor of neutral endopeptidase 24.11, and its use in detecting nanogram quantities of the enzyme by "inhibitor gel electrophoresis".

Authors:  M C Fournié-Zaluski; J M Soleilhac; S Turcaud; R Laï-Kuen; P Crine; A Beaumont; B P Roques
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

Review 4.  The degradation of amyloid beta as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses.

Authors:  Laura Morelli; Ramiro Llovera; Sandra Ibendahl; Eduardo M Castaño
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

Review 5.  Mechanisms of Abeta clearance and catabolism.

Authors:  Suzanne Y Guénette
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

6.  Analysis of PTPRK polymorphisms in association with risk and age at onset of Alzheimer's disease, cancer risk, and cholesterol.

Authors:  Yang Chen; Chun Xu; Sam Harirforoosh; Xingguang Luo; Ke-Sheng Wang
Journal:  J Psychiatr Res       Date:  2017-09-27       Impact factor: 4.791

7.  Effects of HNE-modification induced by Abeta on neprilysin expression and activity in SH-SY5Y cells.

Authors:  Rui Wang; Suqing Wang; James S Malter; Deng-Shun Wang
Journal:  J Neurochem       Date:  2009-02       Impact factor: 5.372

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.